Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/51080
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThor A. Wagneren_US
dc.contributor.authorCatherine M. Kressen_US
dc.contributor.authorIngrid Becken_US
dc.contributor.authorMalee Techapornroongen_US
dc.contributor.authorPakorn Wittayapraparaten_US
dc.contributor.authorSomboon Tansuphasawasdikulen_US
dc.contributor.authorGonzague Jourdainen_US
dc.contributor.authorNicole Ngo-Giang-Huongen_US
dc.contributor.authorMarc Lallemanten_US
dc.contributor.authorLisa M. Frenkelen_US
dc.date.accessioned2018-09-04T04:51:19Z-
dc.date.available2018-09-04T04:51:19Z-
dc.date.issued2010-05-01en_US
dc.identifier.issn00951137en_US
dc.identifier.other2-s2.0-77951773576en_US
dc.identifier.other10.1128/JCM.02062-09en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77951773576&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/51080-
dc.description.abstractA single dose of nevirapine (sdNVP) to prevent mother-to-child transmission of HIV-1 increases the risk of failure of subsequent NVP-containing antiretroviral therapy (ART), especially when initiated within 6 months of sdNVP administration, emphasizing the importance of understanding the decay of nevirapine-resistant mutants. Nevirapine-resistant HIV-1 genotypes (with the mutations K103N, Y181C, and/or G190A) from 21 women were evaluated 10 days and 6 weeks after sdNVP administration and at the initiation of ART. Resistance was assayed by consensus sequencing and by a more sensitive assay (oligonucleotide ligation assay [OLA]) using plasma-derived HIV-1 RNA and cell-associated HIV-1 DNA. OLA detected nevirapine resistance in more specimens than consensus sequencing did (63% versus 33%, P < 0.01). When resistance was detected only by OLA (n = 45), the median mutant concentration was 18%, compared to 61% when detected by both sequencing and OLA (n = 51) (P < 0.0001). The proportion of women whose nevirapine resistance was detected by OLA 10 days after sdNVP administration was higher when we tested their HIV-1 RNA (95%) than when we tested their HIV-1 DNA (88%), whereas at 6 weeks after sdNVP therapy, the proportion was greater with DNA (85%) than with RNA (67%) and remained higher with DNA (33%) than with RNA (11%) at the initiation of antiretroviral treatment (median, 45 weeks after sdNVP therapy). Fourteen women started NVP-ART more than 6 months after sdNVP therapy; resistance was detected by OLA in 14% of the women but only in their DNA. HIV-1 resistance to NVP following sdNVP therapy persists longer in cellular DNA than in plasma RNA, as determined by a sensitive assay using sufficient copies of virus, suggesting that DNA may be superior to RNA for detecting resistance at the initiation of ART. Copyright © 2010, American Society for Microbiology. All Rights Reserved.en_US
dc.subjectMedicineen_US
dc.titleDetection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: Comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assayen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Clinical Microbiologyen_US
article.volume48en_US
article.stream.affiliationsUniversity of Washington, Seattleen_US
article.stream.affiliationsChildren's Hospital and Regional Medical Centeren_US
article.stream.affiliationsIRD Institut de Recherche pour le Developpementen_US
article.stream.affiliationsHarvard School of Public Healthen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsChachoengsao Hospitalen_US
article.stream.affiliationsBuddhachinaraj Hospitalen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.